Crohn's disease medical therapy: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Crohn's disease}} {{CMG}} ==Overiew== ==Treatment== {{main|Treatment of Crohn's disease|Biological therapy for inflammatory bowel disease}} Treatment is only nee...")
 
m (Bot: Removing from Primary care)
 
(18 intermediate revisions by 6 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Crohn's disease}}
{{Crohn's disease}}
{{CMG}}
{{CMG}} ; {{AE}} {{ADG}}


==Overiew==
==Overiew==
==Treatment==
Treatment options include medications, nutrition supplements, [[surgery]], or a combination of these options. The goals of treatment are to control inflammation, correct nutritional deficiencies, and relieve symptoms like [[abdominal pain]], [[diarrhea]], and [[rectal bleeding]]. Treatment for Crohn’s disease depends on the location and severity of disease, [[complication]]s, and the person’s response to previous medical treatments when treated for recurring symptoms. Some people have long periods of remission, sometimes years, when they are free of symptoms. However, the disease usually recurs at various times over a person’s lifetime.


{{main|Treatment of Crohn's disease|Biological therapy for inflammatory bowel disease}}
==Medical Therapy==
Treatment is only needed for people exhibiting symptoms. The therapeutic approach to Crohn's disease is sequential: to treat [[acute (medical)|acute]] disease and then to maintain [[remission]]. Treatment initially involves the use of medications to treat any infection and to reduce inflammation. This usually involves the use of aminosalicylate anti-inflammatory drugs and corticosteroids, and may include antibiotics.
The first step in the management of an acute Crohn's disease attack involves determining the anatomical extent of the disease endoscopically, and the severity of the disease, clinically. This classification is important to determine the necessity for topical (in distal disease) or systemic (in extensive disease) pharmacotherapy. Additionally, the severity of the disease may help determine the prognosis and the requirement for more aggressive intervention. Once the disease goes into remission, the goal of maintenance therapy is to prevent any subsequent acute exacerbations.<br>
*Standard treatment for Crohn's disease depends on extent of involvement and disease severity (e.g. mild, moderate, severe and fulminant)  and can be discussed as follows:
:* 1. '''Mild to Moderate Crohn's Disease'''
:** '''Ileitis and colitis'''
:*** Preferred regimen for illeitis and rt side colitis: Oral budesonide (9 mg/day)
:*** Preferred regimen distal colitis : Topical mesalamine or topical steroids (enemas or suppositories)
:*** Preferred regimen other site :Oral mesalamine (4 g/day) or oral sulfasalazine (3-6 g/day)
:*** Alternative regimen (1): [[Mesalamine]] enemas or suppositories (in patients refractory to topical [[corticosteroid]]<nowiki/>s or oral aminosalicylates.
:*** Alternate regimen (2): Oral [[prednisone]] up to 40-60 mg/day '''AND''' infliximab 5mg/kg at weeks 0, 2, 6 of treatment
:**** Note: Effective dose of [[Sulfasalazine]] is 4-6g/day in 4 doses; [[mesalamine]] is 2-4.6g/day in 3 doses; [[Balsalazide|balasalazine]] 6.75g/day in 3 doses; [[mesalamine]] multimatrix formulation is 2.4 to 4.8 g/day. These drugs are effective within 2.4 weeks.
:**'''Oral lesion'''
:::**Preferred regimen (1): triamcinolone acetonide
:::**Preferred regimen (2): [[Mesalamine|mesalamin]]<nowiki/>e suppository 500 mg qd or bid
:::** Preferred regimen (3):[[Mesalamine (rectal)|mesalamin]]<nowiki/>e enema 2-4 g  q1-3 days
:::** Preferred regimen (4):[[sulfasalazine]] 2g/day '''OR''' [[Mesalamine (oral)|mesalamine compounds]] 1.6g/day '''OR''' [[balsalazide]] 3-6g/day
:::** Alternative regimen (1): [[6-mercaptopurine]] '''OR''' [[azathioprine]] '''AND''' [[infliximab]]
:::*** Note: A combination of oral [[Mesalamine (oral)|mesalamine]] 1.6g/day and [[Mesalamine (rectal)|mesalamine enema]] 4g twice weekly is more effective than oral treatment alone.
:::*'''Gastroduodenal disease'''
:::**Preferred regimen (1):  PPI or H2 antagonist, or sucralfate
:::**Preferred regimen (2):  Oral mesalamine (Pentasa: 2 g/day)
:::*'''Maintaince therapy'''
:::**Preferred regimen for proctitis: Mesalamine suppositories
:::**Preferred regimen for distal colitis : Mesalamine enemas
:::**Preferred regimen for others: Oral sulfasalazine or olsalazine or mesalamine(3-3.6 g/day) or balsalazide
:*'''2. Management of Moderate to Severe Crohn's Disease'''
:**'''Acute Management'''
:*** Preferred regimen (1): Oral [[steroids]] (in patients refractory to aminosalicylates in combination with topical therapy)
:*** Alternate regimen (2): Methotrexate (25 mg/wk i.m and once improvement 15 mg/wk i.m or oral or s.c) (in patients refractory to oral steroids)
:*** Alternative regimen (3):  [[infliximab]] 5mg/kg I.V. at weeks 0,2, and 6 (steroid refractory or [[steroid]] dependent despite adequate [[Mercaptopurine|6-MP]] dosing or intolerant to other regimens)
:*** Alternative regimen (4):  Adalimumab (160 mg s.c at 0 wk and 80 mg/2 wks)
:*** Alternative regimen (5):  Certolizumab pegol (400 mg/4wk s.c)
:*** Alternative regimen (6): Azathioprine (2-3 mg/kg/day) '''OR''' 6-mercaptopurine (1-1.5 mg/kg/day)
:**** Note (1): [[Infliximab]] is contraindicated in patients with untreated latent [[Tuberculosis|TB]], pre-existing demyelinating disorder, [[optic neuritis]], moderate to severe [[Congestive heart failure|CHF]], current or recent [[malignancy]]
:**** Note (2): Transdermal [[Nicotine (transdermal)|nicotine]] is effective in achieving remission.
::* '''Maintenance of Remission'''
::**Preferred regimen (1): [[6-mercaptopurine]] (1.5 mg/kg) '''OR''' [[azathioprine]] (2-2.5 mg/kg)
::**Alternate regimen (2): [[infliximab]] (in patients with successful induction with [[infliximab]])
::**Alternate regimen (3): infliximab and azathioprine therapy
::**Alternate regimen (4): Methotrexate therapy (15 mg/wk i.m) (For methotrexate induced remissions)
::**Alternate regimen (5): Adalimumab therapy (40 mg/wk s.c): For adalimumab induced remissions
::**Alternate regimen (6): Certolizumab pegol therapy (400 mg/ 4wk s.c): For certolizumab pegol induced remissions
::**Alternate regimen (7): Natalizumab therapy (300 mg/ 4wk s.c): For natalizumab induced remissions
::***Note (1) : [[Corticosteroids]] are not recommended for long-term maintenance therapy
::***Note (2) : Monitor CBC every 3 months, monitor periodically for side effects
:* '''3.Management of Severe to Fulminant Crohn's Disease'''
::**'''Acute Management'''
::***Preferred Regimen (1): Maximal oral treatment with [[prednisone]] '''AND''' oral aminosalicylate drugs '''AND''' topical [[mesalamine]]
::***Alternate regimen (2): Infliximab 5mg/kg (if refractory and urgent hospitalization is not necessary)
::***Alternate regimen (3): Intravenous [[corticosteroids]] (if patient presents with toxicity)
::****Note: Failure to show significant improvement within 3-5 days is an indication for [[colectomy]]. [[Infliximab]] may be effective in avoiding [[colectomy]] in patients failing to respond to [[corticosteroids]].
::::**'''Maintenance of Remission'''
::::***Preferred Regimen (1): 6 [[mercaptopurine]]


Once remission is induced, the goal of treatment becomes maintaining remission and avoiding flares. Because of side-effects, the prolonged use of corticosteroids must be avoided. Although some people are able to maintain remission with aminosalicylates alone, many require immunosuppressive drugs.<ref name="HanauerCrohns"/>
===Pharmacotherapy===


On 14 January 2008 the U.S. Food and Drug Administration approved [[natalizumab]] (Tysabri) for both induction of remission and maintenance of remission in Crohns. Natalizumab is humanised monoclonal antibody (MAb), and the first alpha-4 antagonist in a new class of agents called selective adhesion-molecule (SAM) inhibitors. Alpha-4 integrin is required for leukocytes to adhere to the walls of blood vessels and migrate into the gut; natalizumab prevents leukocytes from doing that. Natalizumab was previously approved for multiple sclerosis. However, because it suppresses the immune system, natalizumab has been linked to a very rare adverse effect that is usually fatal if undetected. Leukocytes also protect the body from viruses, and 2 patients on natalizumab, who were also receiving other immuno-suppressive drugs ([[Interferon beta-1a|Avonex]] and Immuran), died of a rare brain infection, [[progressive multifocal leukoencephalopathy]]. Because of this danger, patients must be in a special monitoring program, and natalizumab is given as a mono-therapy.<ref name="FDA-Tysbari">{{cite press release|title=FDA Approves Tysabri to Treat Moderate-to-Severe Crohn's Disease|publisher=U.S. Food and Drug Administration|date=2008-01-14|url=http://www.fda.gov/bbs/topics/NEWS/2008/NEW01775.html|accessdate=2008-01-16
==== Aminosalicylates ====
}}</ref>.As of late December 2007, more than 21,000 MS patients were receiving natalizumab mono-therapy without a single incidence of PML occurring.<ref>.http://www.elan.com/News/full.asp?ID=1091942</ref>.
[[Sulfasalazine]] has been a major agent in the therapy of mild to moderate UC for over 50 years. In 1977 Mastan S.Kalsi et al determined that 5-aminosalicyclic acid (5-ASA and [[mesalazine]]) was the therapeutically active compound in [[sulfasalazine]]. Since then many 5-ASA compounds have been developed with the aim of maintaining efficacy but reducing the common side effects associated with the sulfapyridine moiety in [[sulfasalazine]].<ref> {{cite web | author=S. Kane |year=2006 | title=Asacol - A Review Focusing on Ulcerative Colitis|url=http://www.touchalimentarydisease.com/articles.cfm?article_id=6364&level=2}}</ref>


[[Surgery]] may be required for complications such as obstructions, fistulas and/or abscesses, or if the disease does not respond to drugs within a reasonable time. For patients with an obstruction due to a stricture, two options for treatment are strictureplasty and resection of that portion of bowel. According to a retrospective review at the Cleveland Clinic, there is no [[statistical significance]] between strictureplasty alone versus strictureplasty and resection specifically in cases of duodenal involvement. In these cases, re-operation rates were 31% and 27%, respectively, indicating that strictureplasty is a safe and effective treatment for selected patients with duodenal involvement.<ref name="pmid8918424">{{cite journal | author = Ozuner G, Fazio VW, Lavery IC, Milsom JW, Strong SA | title = Reoperative rates for Crohn's disease following strictureplasty. Long-term analysis | journal = Dis. Colon Rectum | volume = 39 | issue = 11 | pages = 1199-203 | year = 1996 | pmid = 8918424 | doi = }}</ref>
* [[Mesalazine]], also known as 5-aminosalicylic acid, 5-ASA, Asacol, Pentasa and Mesalamine.
* [[Sulfasalazine]], also known as Azulfidine.
* [[Balsalazide]], also known as Colazal.
* [[Olsalazine]], also known as Dipentum.


Recent studies using [[Helminthic therapy]] or [[Hookworm]]s to treat Crohn's Disease and other (non-viral) auto-immune diseases seem to yield promising results.<ref>British Medical Journal [http://gut.bmj.com/cgi/content/full/55/1/136 A proof of concept study establishing Necator americanus in Crohn’s patients and reservoir donors]</ref><ref name="Daily Mail">Daily Mail. [http://www.dailymail.co.uk/pages/live/articles/technology/technology.html?in_article_id=481875&in_page_id=1965  The bloodsucking worm that fights allergies from inside your tummy] 14-09-2007.</ref><ref>[http://www.kuro5hin.org/story/2006/4/30/91945/8971 How to cure your asthma or hayfever using hookworm - a practical guide]. 01-05-2006.</ref>
==== Corticosteroids ====
 
* [[Cortisone]]
* [[Prednisone]]
* [[Prednisolone]]
* [[Hydrocortisone]]
* [[Methylprednisolone]]
* [[Beclometasone]]
* [[Budesonide]]
 
==== Immunosuppressive drugs ====
 
* [[Mercaptopurine]], also known as 6-Mercaptopurine, 6-MP and Purinethol.
* [[Azathioprine]], also known as Imuran, Azasan or Azamun, which metabolizes to 6-MP.
* [[Methotrexate]], which inhibits folic acid
* [[Tacrolimus]]
 
==== [[Biological therapy for inflammatory bowel disease|Biological treatment]] ====
 
* [[Infliximab]]
* [[Visilizumab]]
 
====Contraindicated medications====
 
{{MedCondContrAbs
 
|MedCond = Crohn's disease|Alosetron}}


==References==
==References==
Line 22: Line 102:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Disease]]
[[Category:Autoimmune diseases]]
[[Category:Digestive diseases]]
[[Category:Gastroenterology]]
[[Category:Genetic disorders]]
[[Category:Inflammations]]
[[Category:Conditions diagnosed by stool test]]
[[Category:Abdominal pain]]
[[Category:Needs overview]]

Latest revision as of 21:10, 29 July 2020

Crohn's disease

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Crohn's Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Crohn's disease medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Crohn's disease medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Crohn's disease medical therapy

CDC on Crohn's disease medical therapy

Crohn's disease medical therapy in the news

Blogs on Crohn's disease medical therapy

Directions to Hospitals Treating Crohn's disease

Risk calculators and risk factors for Crohn's disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overiew

Treatment options include medications, nutrition supplements, surgery, or a combination of these options. The goals of treatment are to control inflammation, correct nutritional deficiencies, and relieve symptoms like abdominal pain, diarrhea, and rectal bleeding. Treatment for Crohn’s disease depends on the location and severity of disease, complications, and the person’s response to previous medical treatments when treated for recurring symptoms. Some people have long periods of remission, sometimes years, when they are free of symptoms. However, the disease usually recurs at various times over a person’s lifetime.

Medical Therapy

The first step in the management of an acute Crohn's disease attack involves determining the anatomical extent of the disease endoscopically, and the severity of the disease, clinically. This classification is important to determine the necessity for topical (in distal disease) or systemic (in extensive disease) pharmacotherapy. Additionally, the severity of the disease may help determine the prognosis and the requirement for more aggressive intervention. Once the disease goes into remission, the goal of maintenance therapy is to prevent any subsequent acute exacerbations.

  • Standard treatment for Crohn's disease depends on extent of involvement and disease severity (e.g. mild, moderate, severe and fulminant) and can be discussed as follows:
  • 1. Mild to Moderate Crohn's Disease
    • Ileitis and colitis
      • Preferred regimen for illeitis and rt side colitis: Oral budesonide (9 mg/day)
      • Preferred regimen distal colitis : Topical mesalamine or topical steroids (enemas or suppositories)
      • Preferred regimen other site :Oral mesalamine (4 g/day) or oral sulfasalazine (3-6 g/day)
      • Alternative regimen (1): Mesalamine enemas or suppositories (in patients refractory to topical corticosteroids or oral aminosalicylates.
      • Alternate regimen (2): Oral prednisone up to 40-60 mg/day AND infliximab 5mg/kg at weeks 0, 2, 6 of treatment
        • Note: Effective dose of Sulfasalazine is 4-6g/day in 4 doses; mesalamine is 2-4.6g/day in 3 doses; balasalazine 6.75g/day in 3 doses; mesalamine multimatrix formulation is 2.4 to 4.8 g/day. These drugs are effective within 2.4 weeks.
    • Oral lesion
  • Gastroduodenal disease
    • Preferred regimen (1): PPI or H2 antagonist, or sucralfate
    • Preferred regimen (2): Oral mesalamine (Pentasa: 2 g/day)
  • Maintaince therapy
    • Preferred regimen for proctitis: Mesalamine suppositories
    • Preferred regimen for distal colitis : Mesalamine enemas
    • Preferred regimen for others: Oral sulfasalazine or olsalazine or mesalamine(3-3.6 g/day) or balsalazide
  • 2. Management of Moderate to Severe Crohn's Disease
    • Acute Management
      • Preferred regimen (1): Oral steroids (in patients refractory to aminosalicylates in combination with topical therapy)
      • Alternate regimen (2): Methotrexate (25 mg/wk i.m and once improvement 15 mg/wk i.m or oral or s.c) (in patients refractory to oral steroids)
      • Alternative regimen (3): infliximab 5mg/kg I.V. at weeks 0,2, and 6 (steroid refractory or steroid dependent despite adequate 6-MP dosing or intolerant to other regimens)
      • Alternative regimen (4): Adalimumab (160 mg s.c at 0 wk and 80 mg/2 wks)
      • Alternative regimen (5): Certolizumab pegol (400 mg/4wk s.c)
      • Alternative regimen (6): Azathioprine (2-3 mg/kg/day) OR 6-mercaptopurine (1-1.5 mg/kg/day)
        • Note (1): Infliximab is contraindicated in patients with untreated latent TB, pre-existing demyelinating disorder, optic neuritis, moderate to severe CHF, current or recent malignancy
        • Note (2): Transdermal nicotine is effective in achieving remission.
  • Maintenance of Remission
    • Preferred regimen (1): 6-mercaptopurine (1.5 mg/kg) OR azathioprine (2-2.5 mg/kg)
    • Alternate regimen (2): infliximab (in patients with successful induction with infliximab)
    • Alternate regimen (3): infliximab and azathioprine therapy
    • Alternate regimen (4): Methotrexate therapy (15 mg/wk i.m) (For methotrexate induced remissions)
    • Alternate regimen (5): Adalimumab therapy (40 mg/wk s.c): For adalimumab induced remissions
    • Alternate regimen (6): Certolizumab pegol therapy (400 mg/ 4wk s.c): For certolizumab pegol induced remissions
    • Alternate regimen (7): Natalizumab therapy (300 mg/ 4wk s.c): For natalizumab induced remissions
      • Note (1) : Corticosteroids are not recommended for long-term maintenance therapy
      • Note (2) : Monitor CBC every 3 months, monitor periodically for side effects
  • 3.Management of Severe to Fulminant Crohn's Disease
    • Acute Management
      • Preferred Regimen (1): Maximal oral treatment with prednisone AND oral aminosalicylate drugs AND topical mesalamine
      • Alternate regimen (2): Infliximab 5mg/kg (if refractory and urgent hospitalization is not necessary)
      • Alternate regimen (3): Intravenous corticosteroids (if patient presents with toxicity)

Pharmacotherapy

Aminosalicylates

Sulfasalazine has been a major agent in the therapy of mild to moderate UC for over 50 years. In 1977 Mastan S.Kalsi et al determined that 5-aminosalicyclic acid (5-ASA and mesalazine) was the therapeutically active compound in sulfasalazine. Since then many 5-ASA compounds have been developed with the aim of maintaining efficacy but reducing the common side effects associated with the sulfapyridine moiety in sulfasalazine.[1]

Corticosteroids

Immunosuppressive drugs

Biological treatment

Contraindicated medications

Crohn's disease is considered an absolute contraindication to the use of the following medications:

References

  1. S. Kane (2006). "Asacol - A Review Focusing on Ulcerative Colitis".

Template:WH Template:WS